We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Somaxon Hits Par With IP Suit Over Silenor Generic

Law360 (February 2, 2011, 8:03 PM EST) -- Somaxon Pharmaceuticals Inc. slapped Par Pharmaceutical Cos. Inc. with a patent infringement suit Wednesday over Par's bid for regulatory approval to market generic versions of Somaxon's insomnia drug Silenor.

Somaxon and patent owner ProCom One Inc. lodged their complaint against parent Par and subsidiary Par Pharmaceutical Inc. in the U.S. District Court for the District of Delaware.

The U.S. Food and Drug Administration approved the prescription sleep aid Silenor, an oral tablet formulation of doxepin, in March.

At issue is U.S. Patent Number 6,211,229, titled "Treatment...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.